AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock ...

GlobalData market analysts predict that Elahere could generate up to $1.98bn in revenue for AbbVie by 2030. Credit: ...

Many patients with rheumatic diseases refrain from telling their doctors about all physical and emotional symptoms they’re ...

Pomp Investments investor Anthony Pompliano discusses the likelihood of a Bitcoin boom on 'The Claman Countdown.' The ...

With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...

AbbVie Inc. ( NYSE:ABBV ) will increase its dividend from last year's comparable payment on the 14th of February ...

AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically ...

Alas, this master plan is now in serious doubt. On Nov. 11, the pharmaceutical giant reported that emraclidine failed to meet ...

On Friday, AbbVie Inc (ABBV) stock saw a decline, ending the day at $164.99 which represents a decrease of $-4.64 or -2.74% from the prior close of $169.63. The stock opened at $169.63 and touched a ...

November 12, 2024. More for You ...

Aldeyra (ALDX) announced FDA acceptance of its resubmitted market application for reproxalap and an expansion of its option agreement with AbbVie (ABBV). Read more here.

Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer and full approval earlier this year, was the key asset in AbbVie's $10.1 billion ...